Ivonescimab (SMT112)

Ivonescimab (SMT112) – PD-1/VEGF Bispecific Antibody

Summit is initiating development activities for SMT112 and will do so first in NSCLC indications and plans to start treating patients in clinical studies by the second quarter of 2023.